Abstract
Immunohistochemistry (IHC) is a widely-tested, low-cost and rapid ancillary technique available in all laboratories of pathology. This method is generally used for diagnostic purposes, but several studies have investigated the sensitivity and specificity of different immunohistochemical antibodies as a surrogate test in the determination of predictive biomarkers in non-small cell lung cancer (NSCLC), particularly for Epidermal Growth Factor Receptor (EGFR) gene mutations, Anaplastic Lymphoma Kinase (ALK) gene and ROS1 rearrangements. In this review, a critical examination of the works comparing the consistency of IHC expression and conventional molecular techniques to identify genetic alterations with predictive value in NSCLC is discussed. Summarizing, data on sensitivity and specificity of antibodies against ALK and ROS1 are very consistent and time has come to trust in IHC at least as a cost-effective screening tool to identify patients with rearranged tumors in clinical practice. On the other hand, mutant-specific antibodies against EGFR demonstrate a good specificity but a lowto- fair sensitivity, raising some cautions on their employment as robust predictive biomarkers. A brief comment on preliminary experiences with antibodies against BRAF, RET, HER2 and c-MET is also included.
Keywords: ALK, EGFR, gene mutation, immunohistochemistry, lung cancer, molecular biology, ROS1.
Current Drug Targets
Title:Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
Volume: 18 Issue: 1
Author(s): Giulio Rossi, Moira Ragazzi, Ione Tamagnini, Maria C. Mengoli, Giada Vincenzi, Fausto Barbieri, Silvia Piccioli, Alessandra Bisagni, Tiziana Vavala, Luisella Righi, Silvia Novello, Francesco Gelsomino and Marcello Tiseo
Affiliation:
Keywords: ALK, EGFR, gene mutation, immunohistochemistry, lung cancer, molecular biology, ROS1.
Abstract: Immunohistochemistry (IHC) is a widely-tested, low-cost and rapid ancillary technique available in all laboratories of pathology. This method is generally used for diagnostic purposes, but several studies have investigated the sensitivity and specificity of different immunohistochemical antibodies as a surrogate test in the determination of predictive biomarkers in non-small cell lung cancer (NSCLC), particularly for Epidermal Growth Factor Receptor (EGFR) gene mutations, Anaplastic Lymphoma Kinase (ALK) gene and ROS1 rearrangements. In this review, a critical examination of the works comparing the consistency of IHC expression and conventional molecular techniques to identify genetic alterations with predictive value in NSCLC is discussed. Summarizing, data on sensitivity and specificity of antibodies against ALK and ROS1 are very consistent and time has come to trust in IHC at least as a cost-effective screening tool to identify patients with rearranged tumors in clinical practice. On the other hand, mutant-specific antibodies against EGFR demonstrate a good specificity but a lowto- fair sensitivity, raising some cautions on their employment as robust predictive biomarkers. A brief comment on preliminary experiences with antibodies against BRAF, RET, HER2 and c-MET is also included.
Export Options
About this article
Cite this article as:
Rossi Giulio, Ragazzi Moira, Tamagnini Ione, Mengoli C. Maria, Vincenzi Giada, Barbieri Fausto, Piccioli Silvia, Bisagni Alessandra, Vavala Tiziana, Righi Luisella, Novello Silvia, Gelsomino Francesco and Tiseo Marcello, Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450116666150330114441
DOI https://dx.doi.org/10.2174/1389450116666150330114441 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Synthesis and Biological Applications of Triazole Derivatives – A Review
Mini-Reviews in Organic Chemistry Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism Fluoroquinolones Prophylaxis of Bacterial Infections in Neutropenic Patients: Time to Re-Evaluate
Current Cancer Therapy Reviews Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Methotrexate Induced Pneumonitis: A Review Article
Current Respiratory Medicine Reviews Cancer and Stem Cells
Current Cancer Therapy Reviews A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of Microencapsulate Implants: Patents and Clinical Trials
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL: Novel Signaling Pathway Based Therapeutics in Cancer and Other Diseases
Current Signal Transduction Therapy Targeting CD147 is a Novel Strategy for Antitumor Therapy
Current Pharmaceutical Design Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery